Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $20.10, for a total value of $783,900.00. Following the completion of the transaction, the chief executive officer directly owned 836,347 shares of the company’s stock, valued at approximately $16,810,574.70. This represents a 4.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Xingjuan Chao also recently made the following trade(s):

• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total transaction of $717,600.00.
• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total transaction of $680,550.00.
• On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total transaction of $41,242.36.

CeriBell Stock Up 2.5%

NASDAQ CBLL traded up $0.50 during mid-day trading on Thursday, reaching $20.65. The stock had a trading volume of 78,643 shares, compared to its average volume of 305,204. The company has a fifty day moving average price of $19.16 and a 200 day moving average price of $18.66. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. CeriBell, Inc. has a 1 year low of $10.85 and a 1 year high of $24.33. The stock has a market cap of $781.86 million, a PE ratio of -14.06 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $24.78 million during the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. On average, research analysts expect that CeriBell, Inc. will post -1.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CBLL shares. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of CeriBell in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $23.20.

Hedge Funds Weigh In On CeriBell

Several institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its holdings in shares of CeriBell by 1,945.9% in the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. KCM Capital Inc bought a new position in CeriBell in the 4th quarter worth $21,930,000. Royce & Associates LP bought a new stake in CeriBell during the fourth quarter valued at about $11,695,000. Adage Capital Partners GP L.L.C. bought a new position in shares of CeriBell in the fourth quarter worth about $10,965,000. Finally, CenterBook Partners LP grew its stake in shares of CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after acquiring an additional 389,584 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.